Dedee F Murrell1, Sandra Peña2, Pascal Joly3, Branka Marinovic4, Takashi Hashimoto5, Luis A Diaz6, Animesh A Sinha7, Aimee S Payne8, Maryam Daneshpazhooh9, Rüdiger Eming10, Marcel F Jonkman11, Daniel Mimouni12, Luca Borradori13, Soo-Chan Kim14, Jun Yamagami15, Julia S Lehman16, Marwah Adly Saleh17, Donna A Culton6, Annette Czernik18, John J Zone19, David Fivenson20, Hideyuki Ujiie21, Katarzyna Wozniak22, Ayşe Akman-Karakaş23, Philippe Bernard24, Neil J Korman25, Frédéric Caux26, Kossara Drenovska27, Catherine Prost-Squarcioni28, Snejina Vassileva27, Ron J Feldman29, Adela Rambi Cardones30, Johann Bauer31, Dimitrios Ioannides32, Hana Jedlickova33, Francis Palisson34, Aikaterini Patsatsi35, Soner Uzun23, Savas Yayli36, Detlef Zillikens37, Masayuki Amagai15, Michael Hertl38, Enno Schmidt37, Valeria Aoki39, Sergei A Grando40, Hiroshi Shimizu21, Sharon Baum41, Guiseppe Cianchini42, Claudio Feliciani43, Pilar Iranzo44, Jose M Mascaró44, Cezary Kowalewski22, Russell Hall30, Richard Groves45, Karen E Harman46, M Peter Marinkovich47, Emanual Maverakis48, Victoria P Werth49. 1. Department of Dermatology, St. George Hospital, University of New South Wales, Sydney, Australia. Electronic address: d.murrell@unsw.edu.au. 2. Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Dermatology at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Dermatology, Rouen University Hospital, Rouen, France. 4. Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine, Zagreb, Croatia. 5. Kurume University Institute of Cutaneous Cell Biology, Kurume, Japan. 6. Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 7. Department of Dermatology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York. 8. Department of Dermatology at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 9. Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran. 10. Department of Dermatology and Allergology, University Hospital, Philipps-Universität Marburg, Marburg, Germany. 11. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 12. Department of Dermatology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 13. Department of Dermatology, University Hospital of Bern, Bern, Switzerland. 14. Department of Dermatology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. 15. Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. 16. Department of Dermatology, Mayo Clinic College of Medicine, Rochester, Minnesota. 17. Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt. 18. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. 19. Department of Dermatology, School of Medicine, University of Utah, Salt Lake City, Utah. 20. St. Joseph Mercy Health System, Department of Dermatology, Ann Arbor, Michigan. 21. Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 22. Department of Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland. 23. Department of Dermatology and Venereology, Faculty of Medicine, Akdeniz University, Antalya, Turkey. 24. Department of Dermatology, Reims University Hospital, University of Champagne-Ardenne, Reims, France. 25. Department of Dermatology and the Murdough Family Center for Psoriasis, University Hospitals Case Medical Center, Cleveland, Ohio. 26. Department of Dermatology, Avicenne Hospital, University Paris 13, Bobigny, France. 27. Department of Dermatology and Venereology, Medical Faculty, University of Medicine, Sofia, Bulgaria. 28. Department of Dermatology, Department of Histology, Reference Center for Autoimmune Bullous Diseases, Avicenne Hospital, University Paris 13, Bobigny, France. 29. Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia. 30. Dermatology, Duke University Medical Center, Durham. 31. Division of Molecular Dermatology, Department of Dermatology, Paracelsus Medical University Salzburg, Salzburg, Austria. 32. First Department of Dermatology, Aristotle University, Thessaloniki, Greece. 33. Department of Dermatovenereology, St. Anna University Hospital, Masaryk University, Brno, Czech Republic. 34. Facultad de Medicina, Clínica Alemana, Santiago, Chile. 35. Second Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece. 36. Dermatology Department, School of Medicine, Karadeniz Technical University, Trabzon, Turkey. 37. Department of Dermatology, University of Lubeck, Lubeck, Germany. 38. Department of Dermatology, University Hospital, Marburg, Germany. 39. Departamento de Dermatologia, Universidade de Sao Paulo, Sao Paulo, Brazil. 40. Department of Dermatology, University of California, Irvine, California; Department of Biological Chemistry Cancer Center, University of California, Irvine, California; Research Institute, Institute for Immunology, University of California, Irvine, California. 41. Sheba Medical Center, Dermatology Department, Tel-Hashomer, Ramat-Gan, Israel. 42. Department of Immunodermatology, Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy; Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy. 43. Clinica Dermatologica, Universita' Di Parma, Parma, Italy. 44. Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. 45. St. John's Institute of Dermatology, Guy's & St. Thomas' Hospitals, London, United Kingdom. 46. University Hospitals Leicester, Leicester Royal Infirmary, Leicester, United Kingdom. 47. Department of Dermatology, Stanford University School of Medicine, Stanford, California; Center for Clinical Sciences Research, Palo Alto, California; Division of Dermatology, Department of Veterans Affairs Palo Alto Healthcare System, Palo Alto, California. 48. Department of Dermatology, School of Medicine, University of California, Davis, California. 49. Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Dermatology at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: werth@pennmedicine.upenn.edu.
Abstract
BACKGROUND: Several European countries recently developed international diagnostic and management guidelines for pemphigus, which have been instrumental in the standardization of pemphigus management. OBJECTIVE: We now present results from a subsequent Delphi consensus to broaden the generalizability of the recommendations. METHODS: A preliminary survey, based on the European Dermatology Forum and the European Academy of Dermatology and Venereology guidelines, was sent to a panel of international experts to determine the level of consensus. The results were discussed at the International Bullous Diseases Consensus Group in March 2016 during the annual American Academy of Dermatology conference. Following the meeting, a second survey was sent to more experts to achieve greater international consensus. RESULTS: The 39 experts participated in the first round of the Delphi survey, and 54 experts from 21 countries completed the second round. The number of statements in the survey was reduced from 175 topics in Delphi I to 24 topics in Delphi II on the basis of Delphi results and meeting discussion. LIMITATIONS: Each recommendation represents the majority opinion and therefore may not reflect all possible treatment options available. CONCLUSIONS: We present here the recommendations resulting from this Delphi process. This international consensus includes intravenous CD20 inhibitors as a first-line therapy option for moderate-to-severe pemphigus.
BACKGROUND: Several European countries recently developed international diagnostic and management guidelines for pemphigus, which have been instrumental in the standardization of pemphigus management. OBJECTIVE: We now present results from a subsequent Delphi consensus to broaden the generalizability of the recommendations. METHODS: A preliminary survey, based on the European Dermatology Forum and the European Academy of Dermatology and Venereology guidelines, was sent to a panel of international experts to determine the level of consensus. The results were discussed at the International Bullous Diseases Consensus Group in March 2016 during the annual American Academy of Dermatology conference. Following the meeting, a second survey was sent to more experts to achieve greater international consensus. RESULTS: The 39 experts participated in the first round of the Delphi survey, and 54 experts from 21 countries completed the second round. The number of statements in the survey was reduced from 175 topics in Delphi I to 24 topics in Delphi II on the basis of Delphi results and meeting discussion. LIMITATIONS: Each recommendation represents the majority opinion and therefore may not reflect all possible treatment options available. CONCLUSIONS: We present here the recommendations resulting from this Delphi process. This international consensus includes intravenous CD20 inhibitors as a first-line therapy option for moderate-to-severe pemphigus.
Authors: Daniel Mimouni; Carlos H Nousari; Deborah L Cummins; David J Kouba; Michael David; Grant J Anhalt Journal: J Am Acad Dermatol Date: 2003-12 Impact factor: 11.527
Authors: C Boulard; S Duvert Lehembre; C Picard-Dahan; J S Kern; G Zambruno; C Feliciani; B Marinovic; P Vabres; L Borradori; C Prost-Squarcioni; B Labeille; M A Richard; S Ingen-Housz-Oro; E Houivet; V P Werth; D F Murrell; M Hertl; J Benichou; P Joly Journal: Br J Dermatol Date: 2016-04-03 Impact factor: 9.302
Authors: M Hertl; H Jedlickova; S Karpati; B Marinovic; S Uzun; S Yayli; D Mimouni; L Borradori; C Feliciani; D Ioannides; P Joly; C Kowalewski; G Zambruno; D Zillikens; M F Jonkman Journal: J Eur Acad Dermatol Venereol Date: 2014-10-22 Impact factor: 6.166
Authors: Dedee F Murrell; Benjamin S Daniel; Pascal Joly; Luca Borradori; Masayuki Amagai; Takashi Hashimoto; Frédéric Caux; Branka Marinovic; Animesh A Sinha; Michael Hertl; Philippe Bernard; David Sirois; Giuseppe Cianchini; Janet A Fairley; Marcel F Jonkman; Amit G Pandya; David Rubenstein; Detlef Zillikens; Aimee S Payne; David Woodley; Giovanna Zambruno; Valeria Aoki; Carlo Pincelli; Luis Diaz; Russell P Hall; Michael Meurer; Jose M Mascaro; Enno Schmidt; Hiroshi Shimizu; John Zone; Robert Swerlick; Daniel Mimouni; Donna Culton; Jasna Lipozencic; Benjamin Bince; Sergei A Grando; Jean-Claude Bystryn; Victoria P Werth Journal: J Am Acad Dermatol Date: 2011-11-05 Impact factor: 11.527
Authors: Jacqueline W Mays; Barbara P Carey; Rachael Posey; Luiz Alcino Gueiros; Katherine France; Jane Setterfield; Sook Bin Woo; Thomas P Sollecito; Donna Culton; Aimee S Payne; Martin S Greenberg; Scott De Rossi Journal: Oral Dis Date: 2019-06 Impact factor: 3.511